Anaphylactoid Reaction and Angioedema after Infusion of Recombinant Tissue Plasminogen Activator

Jin Ok Kim, Jae Guk Kim and Soo Joo Lee
Department of Neurology, Eulji University Hospital, Eulji University School of Medicine, Daejon, South Korea

Abstract

An anaphylactoid reaction to recombinant tissue plasminogen activator for thrombolytic treatment of acute ischemic stroke is an uncommon complication. An increased risk of anaphylaxis may be found in patients concomitantly being treated with angiotensin-converting enzyme inhibitors (ACEI). This case report describes a patient who experienced hypotension, tachycardia, dyspnea, orolingual angioedema, and airway obstruction following intravenous administration of alteplase, although she was not taking an ACEI. Possible pharmacologic interactions resulting in excessive serum bradykinin and subsequent systemic hypersensitivity responses are discussed.

Introduction

Recombinant tissue-plasminogen activator (rt-PA) is the only approved pharmacological therapy for acute ischemic stroke that not only improves the prognosis of acute cerebral ischemia but also is relatively safe [1]. Adverse effects include intracerebral, gastrointestinal, genitourinary, retroperitoneal, or pericardial hemorrhage, nausea, vomiting, hypotension, and allergic reactions. Symptomatic cerebral hemorrhage, the most serious adverse event, is reported to occur in 2-9% of patients receiving intravenous (IV) rt-PA therapy. Cases of allergic reaction to IV rt-PA are very rare, reported in only 1.3-5% of patients [2], and command little attention. However, symptoms of an allergic reaction vary widely, from transient and mild oral and lingual angioedema, nausea, and hypotension to life-threatening symptoms that may require intubation or tracheostomy. rt-PA is structurally identical to intrinsic tPA, which accounts for the lower incidence of allergic reactions compared to other thrombolytics, but the risk of an allergic reaction increases in patients who are on an angiotensin-converting enzyme (ACE) inhibitor [3].

Case Report

A 74-year-old female presented to the emergency department with right-sided weakness that started 2 hours prior. She had a past medical history of hypertension, for which she was taking amlodipine 2.5 mg. Neurological examination showed dysarthria, facial paralysis, and weakness of the limbs, and she scored 6 on the National Institutes of Health Stroke Scale (NIHSS). On presentation, her blood pressure was 156/88 mmHg, pulse rate was 106 per minute, respiratory rate was 23, and oxygen saturation was 100%. Examination did not reveal any rashes or wheezes. Normal saline dose was increased, and brain and chest CT did not reveal cerebral hemorrhage or pulmonary embolism. The patient was placed in Trendelenburg position, and colloids were added to her fluid regimen, but her blood pressure continued to decrease. The patient was diaphoretic and developed cold extremities and oral angioedema improved within 20 minutes. However, right hemiparesis and dysarthria persisted, and the NIHSS score did not improve to 5 until discharge.

Discussion

Anaphylaxis is a severe, systemic allergic reaction. An immune reaction to an allergen produces immunoglobulin E (IgE) antibodies. When the same allergen that caused the initial immune reaction enters the body again, it binds to IgE and leads to the secretion of histamine and bradykinin, which in turn cause severe systemic reactions that resemble shock. Symptoms similar to anaphylaxis without concrete evidence of an immune basis are called anaphylactoid reactions. This patient was not previously exposed to rt-PA, and IgE antibody titer was not measured. Therefore, this case cannot be confirmed as anaphylaxis. However, the possibility of cross-reactivity with tPA epitepope cannot be excluded.

Even if this case was not one of anaphylaxis, rt-PA can activate the complement system by increasing the plasma concentrations of C4a, C3a, and C5a, ultimately leading to histamine secretion from mast cells[4]. rt-PA also activates plasmin and produces bradykinin from its precursor, kininogen. Bradykinin is a vasodilator that increases vascular permeability and can cause angioedema [3]. Patients on an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers are at higher risk of developing anaphylaxis or anaphylactoid reactions.

*Corresponding Author: Dr. Soo Joo Lee, Department of Neurology, Eulji University Hospital, Eulji University School of Medicine DunsanSeo-ro 95, Seogu, Daejon, 35233, South Korea; E-mail: sjoolee@eulji.ac.kr


Copyright: © 2017 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A receptor blocker (ARB) can be more susceptible to angioedema. This is because an ACE prevents the breakdown of bradykinin and increases its plasma concentration. Adverse events seen in patients on ACE inhibitors or ARBs, such as angioedema and cough, are also due to the increased concentration of bradykinin [5]. The patient in this case report was not on an ACE inhibitor or ARB, but she still developed symptoms such as hypotension, buccal angioedema, and decreased alertness, which were ameliorated with antihistamine and steroid. This can lead to the diagnosis of an anaphylactoid reaction. Anaphylactoid reactions can improve with supportive therapy alone, but may sometimes require intubation. Attention must be paid to allergic reactions to rt-PA in order to respond in a timely manner.

**Abbreviations**

- rt-PA: Recombinant tissue-Plasminogen Activator
- ACE: Angiotensin-Converting Enzyme
- NIHSS: National Institutes of Health Stroke Scale
- CT: Computed Tomography
- IgE: Immunoglobulin E
- ARB: Angiotensin II Receptor Blocker

**Competing Interests**

The authors declare that they have no competing interests.

**References**